Virtual Library

Start Your Search

Carlos Silva



Author of

  • +

    P2.04 - Immuno-oncology (ID 167)

    • Event: WCLC 2019
    • Type: Poster Viewing in the Exhibit Hall
    • Track: Immuno-oncology
    • Presentations: 1
    • Now Available
    • Moderators:
    • Coordinates: 9/09/2019, 10:15 - 18:15, Exhibit Hall
    • +

      P2.04-81 - Non-Small Cell Lung Cancer Treated with Immunotherapy: Multi-Institutional Experience from Argentina (Now Available) (ID 1893)

      10:15 - 18:15  |  Author(s): Carlos Silva

      • Abstract
      • Slides

      Background

      Immunotherapy (IO) has been established as the standard treatment for metastatic non-small cell lung cancer (NSCLC) patients improving survival. It has been approved both in first line and after platinum-treated patients. We aimed to study the efficacy and tolerability of anti PD-(L)1 inhibitors in pts with NSCLC in Argentina providing more evidence about efficacy and toxicity

      Method

      Metastatic NSCLC patients (pts) treated with immunotherapy in six hospitals between 11/2013 - 2/2019 were included. Data was collected retrospectively by the investigators. Progression-free survival (PFS) and overall survival (OS) were assessed. Cox-regression model was performed for uni- and multivariate analysis. All pts who received at least one dose of immunotherapy were evaluated for efficacy and toxicity.

      Result

      A total of 269 patients were included. Median age (range) was 66 ys (28-88), 164 (61%) were men, 226 (84%) were current/former smokers and 223 (82.9%) had performance status (PS) 0-1. The predominantly histology was non-squamous (N=239; 88.8%), 158 (58.7%) tumors were evaluable for PD-L1 expression and 9 (3.3%) had EGFR mutations. 86 (32%) pts received IO as first-line and 155(57.6%) as second-line therapy. Anti-PD1 antibodies were most commonly administered (83.3%). Baseline brain and liver metastases were present in 50 (18.6%) and 29 (10. 8%) pts, respectively. The overall response rate was 30.4% (76/256). The most common sites of progression were (N=261) bones 142 (54.4%), lung/lymph nodes 74 (28.4%) and brain 26 (10%), visceral 19 (7.3%). Grade ≥ 3 adverse events occurred in 48 pts (17.8%) and 28 (10.4%) pts discontinued treatment due to toxicity. With a median follow up of 15.88 months (95% CI 12.08-19.68), median PFS was 7.26 (95%CI 5.15-9.38) and OS was 15.18 (95%CI 9.47-20-90). In univariate analysis smoking status (p 0.049), PDL1 (p 0.002), PS (p 0.000), corticoid therapy at beginning of IO (p 0.001), grade≥3 toxicity (p 0.027), first line therapy (p=0.003) and driver mutation (p 0.028) were all associated with PFS. Age (p=0.030), PDL1% (p=0.007), corticoid therapy at beginning of IO (p<0.001), grade≥3 toxicity (p=0.012) and first line therapy (p=0.038) were all associated with OS. In multivariate analysis, PDL1 and PS were independently associated with both, PFS (p=0.011 and p=0.000, respectively) and OS (p=0.036 and p<0.001, respectively).

      Conclusion

      Treatment with anti PD-(L)1 inhibitors in the real-world is effective and tolerable, supporting the use of immunotherapy in pts with NSCLC. As previously reported, low PDL1 expression and poor PS confer worst clinical outcomes. Other factors such as age, line of treatment, corticoid use, toxicity and driver mutations may impact treatment response.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.